Security
Madrigal Pharmaceuticals, Inc. Common Stock · MDGL
MDGLNASDAQCommon stockCurrentCIK 1157601Updated Oct 6, 2026
Name history
MADRIGAL PHARMACEUTICALS, INC. · through Sep 28, 2026SYNTA PHARMACEUTICALS CORP · through Aug 1, 2016
MDGL price & chart
Loading TradingView…
NASDAQ:MDGL on TradingView ↗About the company
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by the FDA for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). For more information, visit www.madrigalpharma.com.
In the news
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) ↗
Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize News provided by Equity Insider Jan 02, 2026, 13:29 ET Share this article Share to X Share this article Share to X Issued on behalf of Avant Technologies Inc. VANCOUVER, BC , Jan. 2, 2026 /PRNewswire/ -- Equity Insider News Commentary – The gene ↗
Seeking Alpha
Madrigal anticipates late 2027 MAESTRO-NASH OUTCOMES readout while planning 2,000+ patient MAESTRO-CSPH study ↗
Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2026 Earnings Call Transcript ↗
Baron Health Care Fund: Q3 2026 New Positions And Exits ↗
SEC disclosures
MADRIGAL PHARMACEUTICALS, INC. files 8-K: Material Event ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
144 filing
144 filing
144 filing
Show 5 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
SCHEDULE 13G/A - filed by BlackRock, Inc. regarding MADRIGAL PHARMACEUTICALS, INC.
144 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 1,362,457,000Source | 1,073,265,000Source | 1,244,645,000Source | 1,015,381,000Source | 1,099,789,000Source | 1,227,327,000Source | 996,629,000Source | 1,082,280,000Source | 1,259,589,000Source | 1,042,247,000Source | 640,547,000Source | 362,572,000Source |
| Property, Plant and Equipment, NetUSD | 2,913,000Source | 2,268,000Source | 11,592,000Source | 1,615,000Source | 1,695,000Source | 8,035,000Source | 1,901,000Source | 1,742,000Source | 1,499,000Source | 2,190,000Source | 1,553,000Source | 601,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 295,694,000Source | 232,684,000Source | 292,726,000Source | 186,193,000Source | 494,597,000Source | 227,033,000Source | 183,646,000Source | 622,517,000Source | 198,693,000Source | 100,019,000Source | 99,915,000Source | 331,549,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 113,285,000Source | 30,463,000Source | 192,311,000Source | 79,231,000Source | 6,899,000Source | 187,356,000Source | 61,428,000Source | — | 134,476,000Source | 53,822,000Source | — | — |
| Inventory, NetUSD | 69,317,000Source | 8,715,000Source | 99,391,000Source | 63,497,000Source | 7,072,000Source | 112,070,000Source | 55,241,000Source | 854,000Source | 74,841,000Source | 34,068,000Source | — | — |
| Assets, CurrentUSD | 1,346,680,000Source | 1,063,666,000Source | 1,199,180,000Source | 1,003,356,000Source | 1,091,728,000Source | 1,182,307,000Source | 987,979,000Source | 1,073,952,000Source | 1,245,770,000Source | 1,032,927,000Source | 637,281,000Source | 361,369,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 49,329,000Source | 20,861,000Source | 68,570,000Source | 58,604,000Source | 14,963,000Source | 64,955,000Source | 23,242,000Source | 14,035,000Source | 47,804,000Source | 13,786,000Source | 3,150,000Source | 2,595,000Source |
| Operating Lease, Right-of-Use AssetUSD | 5,387,000Source | 2,512,000Source | 5,578,000Source | 5,862,000Source | 1,456,000Source | 6,203,000Source | 2,110,000Source | 1,586,000Source | 4,939,000Source | 2,401,000Source | 1,713,000Source | 602,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 736,725,000Source | 296,110,000Source | 720,921,000Source | 319,403,000Source | 242,669,000Source | 683,873,000Source | 285,992,000Source | 231,521,000Source | 656,900,000Source | 287,864,000Source | 235,214,000Source | 165,183,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 2,000Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source |
| Retained Earnings (Accumulated Deficit)USD | -2,031,891,000Source | -1,742,766,000Source | -2,242,796,000Source | -1,917,701,000Source | -1,635,802,000Source | -2,184,857,000Source | -1,875,420,000Source | -1,483,831,000Source | -2,090,466,000Source | -1,802,182,000Source | -1,336,290,000Source | -962,660,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 1,068,000Source | 1,271,000Source | 808,000Source | 1,111,000Source | -368,000Source | 1,082,000Source | 389,000Source | -172,000Source | 873,000Source | 468,000Source | 468,000Source | -32,000Source |
| Stockholders' Equity Attributable to ParentUSD | 625,732,000Source | 777,155,000Source | 523,724,000Source | 695,978,000Source | 857,120,000Source | 543,454,000Source | 710,637,000Source | 850,759,000Source | 602,689,000Source | 754,383,000Source | 405,333,000Source | 197,389,000Source |
| Additional Paid in Capital, Common StockUSD | 2,656,553,000Source | 2,518,648,000Source | 2,765,710,000Source | 2,612,566,000Source | 2,493,288,000Source | 2,727,227,000Source | 2,585,666,000Source | 2,334,760,000Source | 2,692,280,000Source | 2,556,095,000Source | 1,741,153,000Source | 1,160,079,000Source |
| Liabilities and EquityUSD | 1,362,457,000Source | 1,073,265,000Source | 1,244,645,000Source | 1,015,381,000Source | 1,099,789,000Source | 1,227,327,000Source | 996,629,000Source | 1,082,280,000Source | 1,259,589,000Source | 1,042,247,000Source | 640,547,000Source | 362,572,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 391,406,000Source | 177,847,000Source | 374,204,000Source | 196,503,000Source | 125,162,000Source | 338,259,000Source | 167,237,000Source | 114,341,000Source | 310,288,000Source | 169,277,000Source | 118,548,000Source | 115,894,000Source |
| Operating Lease, Liability, CurrentUSD | 1,083,000Source | 878,000Source | 1,034,000Source | 1,049,000Source | 557,000Source | 1,697,000Source | 1,016,000Source | 542,000Source | 1,018,000Source | 983,000Source | 527,000Source | 602,000Source |
| Accounts Payable, CurrentUSD | 44,941,000Source | 45,966,000Source | 34,514,000Source | 37,975,000Source | 8,994,000Source | 60,801,000Source | 42,056,000Source | 21,528,000Source | 48,878,000Source | 43,599,000Source | 28,041,000Source | 23,831,000Source |
| Operating Lease, Liability, NoncurrentUSD | 5,566,000Source | 1,176,000Source | 5,923,000Source | 4,524,000Source | 900,000Source | 5,284,000Source | 750,000Source | 1,045,000Source | 6,731,000Source | 1,018,000Source | 1,186,000Source | 0Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 345,382,000Source | 131,003,000Source | 338,656,000Source | 157,479,000Source | 115,611,000Source | 275,761,000Source | 124,165,000Source | 92,271,000Source | 260,392,000Source | 124,695,000Source | 89,980,000Source | 91,461,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 1,114,749,000Source | 1,003,627,000Source | — | 802,024,000Source | 1,062,794,000Source | — | 848,068,000Source | 1,059,063,000Source | — | 931,251,000Source | 634,131,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 339,753,000Source | 117,087,000Source | 340,794,000Source | 118,376,000Source | 116,607,000Source | 340,330,000Source | 118,005,000Source | 116,135,000Source | 339,881,000Source | 117,569,000Source | 115,480,000Source | 49,289,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 339,753,000Source | 117,087,000Source | 340,794,000Source | 118,376,000Source | 116,607,000Source | 340,330,000Source | 118,005,000Source | 116,135,000Source | 339,881,000Source | 117,569,000Source | 115,480,000Source | 49,289,000Source |
| Other Assets, Noncurrent | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | -73,238,000Source | -288,284,000Source | -465,892,000Source | -373,630,000Source | -295,350,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 386,000Source | 379,000Source | 1,506,000Source | 1,096,000Source | 527,000Source | 467,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 34,018,000Source | 20,931,000Source | 98,130,000Source | 79,880,000Source | 49,735,000Source | 31,625,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 52,880,000Source | 7,606,000Source | 80,654,000Source | 53,822,000Source | — | — |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 22,187,000Source | 21,173,000Source | 36,978,000Source | 34,068,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -167,435,000Source | -88,891,000Source | -189,553,000Source | -455,572,000Source | -324,230,000Source | -224,857,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 192,191,000Source | 163,878,000Source | 32,320,000Source | -274,386,000Source | -502,520,000Source | 206,686,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 3,849,000Source | 0Source | 467,000Source | 1,462,000Source | 1,479,000Source | 217,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 2,329,000Source | 8,640,000Source | 255,984,000Source | 735,062,000Source | 595,116,000Source | 313,451,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 28,405,000Source | 83,627,000Source | 98,764,000Source | 5,104,000Source | -231,634,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 300,694,000Source | 237,684,000Source | 292,881,000Source | 191,193,000Source | 232,188,000Source | 188,646,000Source | 203,783,000Source | 105,019,000Source | 99,915,000Source | 331,549,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 26,252,000Source | 17,898,000Source | 35,371,000Source | 25,159,000Source | 34,018,000Source | 20,931,000Source | 98,130,000Source | 79,880,000Source | 49,735,000Source | 31,625,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | 449,000Source | 436,000Source | 1,604,000Source | 2,089,000Source | 2,414,000Source | 797,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 1,114,749,000Source | 1,003,627,000Source | — | 802,024,000Source | — | 848,068,000Source | — | 931,251,000Source | 634,131,000Source | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | -2,779,000Source | 0Source | — | — | — | — | -2,779,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 108,146,000Source | 48,130,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 7,451,000Source | 3,679,000Source | 7,940,000Source | 3,264,000Source | 7,819,000Source | 3,297,000Source | 22,309,000Source | 14,671,000Source | — | — |
| Investment Income, InterestUSD | — | — | 10,308,000Source | 13,019,000Source | 7,104,000Source | 8,227,000Source | 8,243,000Source | 9,370,000Source | 37,364,000Source | 46,654,000Source | 19,578,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -114,190,000Source | -106,964,000Source | -57,939,000Source | -42,281,000Source | -94,391,000Source | -73,238,000Source | -288,284,000Source | -465,892,000Source | -373,630,000Source | -295,350,000Source |
| Operating Costs and ExpensesUSD | — | — | 18,122,000Source | 2,152,000Source | 40,007,000Source | 9,065,000Source | 26,847,000Source | 4,513,000Source | 56,148,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 401,243,000Source | 178,479,000Source | 420,560,000Source | 260,004,000Source | 404,060,000Source | 216,561,000Source | 1,258,500,000Source | — | 380,496,000Source | 293,571,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -293,000Source | 0Source | -795,000Source | -42,000Source | -2,092,000Source | 0Source | -463,000Source | — | — | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | — | — | — | — | — | 350,381,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Inventory Write-down | — | — | — | — | —Source | — | — | — | — | — | — | — |
| Proceeds from Stock Options Exercised | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 287,268,000Source | 62,175,000Source | 364,252,000Source | 212,802,000Source | 311,337,000Source | 137,250,000Source | 958,403,000Source | 180,133,000Source | 0Source | — |
| Cost of RevenueUSD | — | — | — | — | — | — | — | 4,513,000Source | — | 6,233,000Source | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 209,117,000Source | 107,585,000Source | 289,375,000Source | 196,858,000Source | 268,521,000Source | 167,876,000Source | 813,827,000Source | 435,057,000Source | — | — |
| Operating Income (Loss)USD | — | — | -113,975,000Source | -116,304,000Source | -56,308,000Source | -47,202,000Source | -92,723,000Source | -79,311,000Source | -300,097,000Source | -497,875,000Source | -380,496,000Source | -293,571,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -293,000Source | 0Source | -795,000Source | -42,000Source | -2,092,000Source | 0Source | -463,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -114,190,000Source | -106,964,000Source | -57,939,000Source | -42,281,000Source | -94,391,000Source | -73,238,000Source | -288,284,000Source | -465,892,000Source | -373,630,000Source | -295,350,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -5.08Source | -4.92Source | -1.99Source | -1.5Source | -3.25Source | -2.61Source | -12.85Source | -21.9Source | -19.99Source | -17.23Source |
| Earnings Per Share, DilutedUSD per share | — | — | -5.08Source | -4.92Source | -1.99Source | -1.5Source | -3.25Source | -2.61Source | -12.85Source | -21.9Source | -19.99Source | -17.23Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 22,482,502Source | 21,745,929Source | 29,145,271Source | 28,232,604Source | 29,032,422Source | 28,085,234Source | 22,434,310Source | 21,272,962Source | 18,687,774Source | 17,137,201Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 22,482,502Source | 21,745,929Source | 29,145,271Source | 28,232,604Source | 29,032,422Source | 28,085,234Source | 22,434,310Source | 21,272,962Source | 18,687,774Source | 17,137,201Source |
| Interest Expense (non-operating)USD | — | — | 7,451,000Source | 3,679,000Source | 7,940,000Source | 3,264,000Source | 7,819,000Source | 3,297,000Source | 22,309,000Source | 14,671,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | — | — | — | — | — | — | — | 678,008,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 108,146,000Source | 48,130,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -158,500,000Source | — | — | — |
| Interest ExpenseUSD | — | — | — | 3,679,000Source | — | — | — | 3,297,000Source | — | — | 12,712,000Source | 3,964,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | — | — | — | — | — | 6,073,000Source | — | 31,983,000Source | — | — |
| Interest Income, OtherUSD | — | — | — | — | — | — | — | — | — | — | — | 2,185,000Source |
| Investment Income, InterestUSD | — | — | 10,308,000Source | 13,019,000Source | 7,104,000Source | 8,227,000Source | 8,243,000Source | 9,370,000Source | 37,364,000Source | 46,654,000Source | 19,578,000Source | — |
| Operating Costs and ExpensesUSD | — | — | 18,122,000Source | 2,152,000Source | 40,007,000Source | 9,065,000Source | 26,847,000Source | 4,513,000Source | 56,148,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 401,243,000Source | 178,479,000Source | 420,560,000Source | 260,004,000Source | 404,060,000Source | 216,561,000Source | 1,258,500,000Source | — | 380,496,000Source | 293,571,000Source |
| Other IncomeUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
Filing attachments
tm2617490d1_ex99-2.htm · S-8 · 2026-06-17
Exhibit 99.2 MADRIGAL PHARMACEUTICALS, INC. 2026 STOCK PLAN NON-QUALIFIED STOCK OPTION AGREEMENT GRANT NOTICE Name of Participant: Grant Date of the Option (the “Grant Date”): Number of Shares of Stock Covered by the Option: Purchase Price Per Share of Stock: Vesting Commencement Date: Vesting of Award: Subject to the Participant’s continuous Service Relationship from the Grant Date through each of the following applicable dates (each such date, a “Vesting Date”), the Option s…
Read attachment ↗tm2522007d1_ex99-1.htm · 8-K · 2025-07-30
EX-99.1 2 tm2522007d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resmetirom) Combining Rezdiffra with the oral GLP-1, SYH2086, offers potential for a best-in-class MASH treatment in a o…
Read attachment ↗d916063dex991.htm · 8-K · 2025-03-11
EX-99.1 2 d916063dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Madrigal Appoints Jacqualyn A. Fouse, Ph. D. to Its Board of Directors Fred Craves, Ph. D. to retire from Madrigal’s Board of Directors in July 2025 ───────────────────────────────────────────────────────────────────────────────── CONSHOHOCKEN, Pa., Mar. 11, 2025 - Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatiti…
Read attachment ↗d924231dex991.htm · 8-K · 2025-02-26
EX-99.1 2 d924231dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra ™ (resmetirom) in Patients with Compensated MASH Cirrhosis Fourth-quarter and full-year 2024 Rezdiffra net sales of $103.3 million and $180.1 million, respectively As of year-end 2024, more than 11,800 patients on Rezdiffra Reports cash, cash equivalents, restrict…
Read attachment ↗d925380dex991.htm · 8-K · 2025-01-13
EX-99.1 2 d925380dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra Preliminary fourth-quarter and full-year 2024 Rezdiffra™ (resmetirom) net sales ranges of $100 million to $103 million and $177 million to $180 million, respectively Preliminary year-end 2024 cash, cash equivalents, restricted cash and marketable securities of approximately $931 milli…
Read attachment ↗